BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

BMRA

Biomerica Inc.
Nasdaq · In vitro & in vivo diagnostic substances (SIC 2835) · FY ends 31 May

Revenue, quarterly

$1M−8.3% year on year
$10M$5M$0
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 15 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

0.9%−12.1 pp year on year
20%10%0%
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 15 Oct 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$3M−10.5% year on year
$15M$10M$5M$0
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 15 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$5M
$5M$0−$5M−$10M
Q1 ’20Q2 ’21Q3 ’22Q3 ’23Q4 ’24
Company filings · 10-K filed 29 Aug 2025 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty